NHS Trusts and Provider Collaborative Engagement Session

18th of July 2024





Agenda



| Item No | Item | Time | Presenter |
|---------|--|---------------|---|
| 1. | Introductions and scene setting | 10:00 - 10:10 | Jason Bloomfield Customer Account Director |
| 2. | Integrated Resource Management Challenges & Opportunities | 10.10 - 10.30 | Alison Tonge Executive Director of Strategy/Planning and Innovation |
| 3. | Prioritisation of Current Challenges #1 – Group Input What are the challenges for better resource management & driving-out efficiencies | 10.30 - 10.45 | Terry Huff Productivity Lead |
| 4. | West Yorkshire Association of Acute Trusts Harnessing efficiencies through provider collaboratives- pathology procurement | 10:45 - 11.05 | Ben Roberts Associate Director of Finance |
| 5. | NUH- Financial Transformation using Nottingham's Wave programme Reducing waste and improving the quality of services of services provided | 11:05 - 11:25 | Kim Fletcher (Transformation Programme Lead NUH WAVE) Scott Hodgson (Head of Clinical Accounting and Costing Transformation) |
| 6. | NHS Supply Chain Value in Procurement | 11.25 - 11:40 | Hamish Makanji Head of Hospital Care |
| 7. | Comfort Break | 11:40 - 11:50 | |
| 8. | Opportunities for Specialised Services Delegation using the Power of new flexibilities: The Provider Selection Regime (PSR) | 11.50 - 12.05 | Collette Palmer Associate Director of Procurement (Specialised Commissioning) |
| 9. | Prioritisation of Current Challenges #2 – Group Input A review of Item 2 in light of knowledge shared | 12.05 - 12:20 | Terry Huff Productivity Lead |
| 10 | Summary / Outcomes / Next Steps / Close | 12:20 - 12:30 | Chair |

4 6

è



Introduction

Jason Bloomfield, Customer Account Director NHS Arden & GEM CSU









- **1.** Purpose of this morning
- 2. A quick overview of CSU's and NHS Arden & GEM
- 3. Challenge brings opportunity
- 4. Key messages from Month 2



Purpose of this morning



- How can Finance and Procurement work together to drive substantial improvements and waste reduction across our health and care systems?
- What are the tools and support needed?











A little bit about Arden & GEM



CUSTOMERS AND SYSTEMS 90+

Working with a customer base of 90+ organisations across health systems

- NHS England
- ICSs/ICBs
- Providers
- Primary Care
- Local Authorities
- Department of Health and Social Care

Our customer satisfaction score remains at 4.1 out of 5

Quality assurance







INVESTORS IN PEOPLE[®]

We invest in people Gold





National award wins + 4 shortlisting's PPP



Data-Driven Transformation for a project which improved care for people with frailty and dementia.



Service Desk of the Year in the large enterprise category



Digital solution for social care for the Adult Social Care Client Level Directions project

Challenge brings opportunity



The No.1 challenge for NHS Leaders

"How do they balance their books while protecting patient safety given many organisations are having to achieve significant efficiency savings?"

NHS Confederation – The state of NHS finances 2024/25





Challenge brings opportunity




So, what can we collectively achieve?

- 1. NHS Leaders plan to reduce spending on agency, locums, bank staff and freezing vacancies
- 2. Deliver services more efficiently
- 3. Redesign how care is delivered



Short term versus the longer term




- Efficiency targets need to be delivered now [5% 11%]
- How do we address productivity in a strategic way?
- The role of social care and community settings



Key messages from Month 2

- Not where we need to be
- What do we need to do?
- Credibility







Arden&GEM Integrated Resource Planning Network HELPING SYSTEMS TO IMPROVE VALUE



Connected Resource Management

Benefits of connected planning across Healthcare Providers





The Triple Aim in the NHS: The Triple Aim framework aims to improve health outcomes, improve quality of care and access and demonstrate greater efficiency and value from the investment. We have a legal duty to make good decisions

Key Decisions :

1.Reallocating Funding to the Right Care

 Invest in Prevention and Community Services: Shifting funds from high-cost, acute interventions to preventative and community-based care to improve overall health outcomes.

2. Releasing Funding for Reinvestment

• Focus on Productivity and Reducing Waste: Implementing best practices, digitalfirst approaches, workforce efficiency, optimal utilisation, and commercial efficiencies to maximize value.


3. Delivering Care Centred Around Patients' Needs

• **Patient and Population-Focused Care**: Ensuring care is designed to meet the needs of patients and populations rather than organisational convenience.

Assurance to Stakeholders:

ntegrated Resource lanning Network

 Transparency and Accountability: Demonstrating the best use of resources to patients, taxpayers, and stakeholders through continuous improvement and measurable outcomes.







• Research in social sciences, economics and psychology highlights the importance of improving decision-making across four main areas.

Quality of decisions

- Decisions are framed against clear objectives, with benefit criteria and measures for impact
- Relevant and reliable information is provided across multiple measures to enable the decision.

Impact of decisions

- Outcomes from each decision choice are clear, as are trade-offs between factors such as money, capacity, workforce, performance, outcomes, quality
- Decisions are made at the right level for the impact required, at an operational or strategic level.

Action orientated

• Decisions can be acted on within a timeframe that enables the benefits to be delivered.

Productive

- Decisions are made efficiently the organisation sets out how and where decisions are made
- Increasing the percentage of available management time for making decisions.

Improving decision-making processes alone won't enhance the value delivered by these decisions to achieve optimal results we need to have enterprise- wide resource management decisions **connected together**.







A highly connected organisation focuses on ensuring resources are managed optimally through interconnectivity of data, intelligence, processes, governance, and systems aligned across three dimensions:

Vertically – from board to operations, strategic to operational

Horizontally – across functions or delivery units working together to deliver end results, such as a pathway of care

Externally – serving populations and places to deliver value for specific population groups, e.g. frail elderly or young black males with mental illness in a neighbourhood







| Dimension | Resource management capability | Best practice |
|------------|---|--|
| | Strategic connected to operational | Roll up and roll down of operational to strategic, from monthly, quarterly and annual to three yearly. |
| Vertical | Connect many bottom-line measures | Each unit has a clear set of measures for triple value. Connect these unit measures across the value chain to the overall objective. |
| | Real-time monitoring and manage performance to deliver results | Dynamically changing plans to deliver the results required, influencing resource decisions, operational delivery. |
| | Aligned roles, processes and practices | Effective and efficient cross-functional collaboration, between finance, workforce, capacity and demand. |
| Horizontal | | Cross business unit collaboration to plan the end results for a pathway of care. |
| | Connected data, intelligence and resource systems | A single source of intelligence across key results [triple value performance], workforce, finance, demand and capacity |
| | Connect with patients, populations and places | Integrating triple value measures from target areas for biggest impact and acting on performance variation. |
| External | Connect with suppliers, life sciences and innovators | Align supplier product value (price, quality, social value) to key pathways and business units. Align life science drugs, devices and technologies adoption decisions with consistent value framework. |





NHS

Industry has long recognised the importance of integrating - resource management, advanced intelligence and decision functions within their organisations.

Indeed, research papers abound with empirical evidence which demonstrates the significant impact of integrating realtime operational information systems and business planning on key results such as market share, sales, efficiency and satisfaction. However there is little if any evidence in the NHS of integrated resource management and the impact on benefits for patients and populations.

Key improvements observed include: •Increasing revenue by 52% •Improving forecast accuracy by 31% •Enhancing perfect order and customer service by 31% •Better supply planning and schedule adherence by 31% •Improving new product launch by 28% •Reducing inventory by 27% •Better translation of demand into procurement requirements by 21% •Improved capital planning and asset management by 21% •Developing and executing demand-shaping programs by 20% •Enhancing logistics planning by 19% •Improving asset utilisation by 17% (Palmatier & Crum, 201






Our Approach to Connected Planning

Arden&GEM

Integrated Resource Planning Network










/:naplan

- The centre enables members to benefit from development of integrated planning models for the NHS.
- Shared learning and best practice on achieving high performance in resource management methodologies, interventions, modelling scenarios, forecasting and governance controls.
- Utilising an industry best practice technology solution to facilitate integrated planning through a suite of models
- Services delivered to the NHS by the NHS

The Centre of Integrated Planning includes a Data Hub for centralised decision-making, a Design Authority for quality design processes, structured Model Development Process, a Community of Practice for sharing best practices, and a Standard Business Case and ROI framework for evaluating investments.

We are continuing to work with a range of external partners to accelerate our development of this centre of excellence.

Communities of practice- Adopt and Learn







- These examples illustrate the tangible benefits of connected decision-making in the NHS, highlighting the potential for improved productivity, efficiency, and collaboration across health and care systems.
- Example 1: Financial planning and productivity gains
- By integrating financial planning metrics, NHS Trusts have demonstrated significant productivity gains. For instance, one Trust's approach to financial planning has resulted in each full-time equivalent (FTE) employee saving 3-4 days per month previously spent on manually aggregating and adjusting data for resubmission into their general ledger. This translates to a 20% productivity gain each month, regardless of the organisation's size. Furthermore, by connecting finance with workforce data, budget holders are saving 20% of their time previously spent on spreadsheets, allowing them more time to advise operational staff effectively.
- Example 2: System demand and capacity planning
- An Integrated Care System (ICS) has implemented an integrated business planning platform. This platform replicates NHS England planning submissions with connected assumptions and scenarios, consolidating ICS-wide reporting. The pilot project demonstrated several benefits:
- A system-wide view of demand and capacity on beds and services for acute, community, local authority, and hospice services
- Dynamic reports viewed across different dimensions and levels of detail to improve operational efficiency
- Forecasting capabilities allowing users to adjust factors like admissions and capacity to understand their impact on demand and capacity shortfall
- Improved collaboration between system partners, creating a shared understanding and facilitating targeted actions to improve patient/service user flow through the system.





NHS

Projected Financial Savings



The Ambulance Trust is on the brink of a significant overhaul, poised to replicate the successful ICS digital transformation. By implementing a series of IT enablers, the Trust is expected to realise substantial financial and operational benefits. This case study outlines the projected potential benefits, extrapolated from the achievements witnessed by the ICS in the same region.

Initiatives for Transformation:

The proposed IT enablers for include:

Integrated Planning - Creating robust forecasting mechanisms for demand-driven workforce planning.

PAS/Bank/Agency Integration - Enhancing resource allocation and management to align with actual service demand.

GRS – Time & Attendance - Implementing automated timesheet systems to ensure accurate payroll processing.

Virtualised Scheduling - Developing a trust-wide rostering system for improved staff and bed management, operational 7 days a week.

Anticipated Financial Benefits with extrapolated data from the achievements witnessed by Mids & South Essex FT implementing the same enablers:

| Financial Benefit Areas | Description | ICS Quantitative Achievement | Potential Annual Savings for the ICS |
|-------------------------|---|---|--|
| | By analysing complex discharges and using shared information systems, the ICS achieved a 5% reduction | 5% reduction on 1176 potential readmissions | |
| Reduced Readmissions | in emergency readmissions post-discharge. | = 58.8 fewer readmissions | £94,980.80 (at £1,616 per readmission) |
| | The ICS targeted delays in care and improved patient | 5% improvement on 23,725 lost bed days = | |
| Improved Patient Flow | flow by 5%. | 1,186.25 recovered bed days | £296,562.50 (at £250 per bed day) |
| | The ICS utilised the excess capacity of 31 beds in | | £582,800.00 (at £18,800 per virtual ward bed |
| Virtual Wards | virtual wards. | Savings from 31 virtual ward beds | annually) |
| Total Annual Savings | Projected Total Annual Savings | | £974,343.30 |

Note: total annual saving of approximately £974,343.30 by adopting the strategies that have proved successful in the ICS.





NHS

The IBP is a **dynamic planning platform**, that is informed by actual performance and reforecasting. It provides analysis across 5 integrated elements to allow for **dynamic planning decisions**, preventing a static annual process.

OLD WORLD

NEW WORLD




- Connected
- Collaborative
- Decision driven
- Optimised
- Purpose built
- Executable
- Agile
- Positive





| Q Find | | | | | | | | | | | î↓ ⊚ Щ | ≣≀ 🕒 … |
|------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | Apr 24 | May 24 | Jun 24 | Jul 24 | Aug 24 | Sep 24 | Oct 24 | Nov 24 | Dec 24 | Jan 25 | Feb 25 | Mar 25 |
| Forecast- Admission | 3,707 | 4,577 | 3,724 | 3,712 | 4,900 | 4,155 | 4,508 | 5,360 | 4,197 | 3,994 | 5,020 | 4,15 |
| Forecast - AVG LoS | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 | 5. |
| Forecast - Discharges | 3,631 | 4,647 | 3,701 | 3,713 | 4,866 | 4,093 | 4,448 | 5,414 | 4,248 | 4,002 | 5,008 | 4,13 |
| Forecast - Occupied Beds | 752 | 682 | 706 | 704 | 738 | 800 | 860 | 806 | 755 | 746 | 759 | 78 |
| Forecast Bed Capacity | 707 | 707 | 707 | 707 | 707 | 679 | 679 | 679 | 650 | 650 | 650 | 650 |
| Forecast - Occupancy | 97% | 98% | 98% | 98% | 103% | 113% | 123% | 119% | 122% | 115% | 115% | 1199 |
| Forecast - Surplus/(Deficit) | -45 | 25 | 1 | 3 | -31 | -121 | -182 | -127 | -104 | -96 | -109 | -136 |



| | Apr 24 | May 24 | Jun 24 | Jul 24 | Aug 24 | Sep 24 | Oct 24 | Nov 24 | Dec 24 | Jan 25 | Feb 25 | Mar 25 |
|-------------------------|--------|--------|--------|--------|---------|---------|---------|---------|---------|---------|---------|---------|
| Occupancy % | 96.6% | 98.1% | 98.1% | 98.3% | 103.3% | 113.3% | 123.1% | 119.2% | 122.0% | 115.2% | 115.4% | 119.0% |
| Input Target Ocupancy % | - | - | 92.0% | 92.0% | 92.0% | 92.0% | 92.0% | 92.0% | 92.0% | 92.0% | 92.0% | 92.0% |
| ** | | | | | | | | | | | | |
| Adjust Admission by | | | -7.70% | -7.91% | -13.42% | -26.67% | -38.92% | -32.45% | -37.53% | -29.01% | -27.91% | -33.87% |
| Adjust LoS by | | | -0.35 | -0.36 | -0.64 | -1.20 | -1.76 | -1.54 | -1.69 | -1.31 | -1.32 | -1.53 |


- Multi-year multi-site demand and capacity planning model linking in hospital and out of hospital activity
- Machine learning provides a baseline forecast of future expected demand, allowing for weekend and seasonal variations
- **Data and forecasts** are refreshed on a weekly basis through a managed service and users can compare current forecasts to historic to measure impact of any interventions introduced.
- End user can test scenarios to understand the impact of varying capacity, admissions, and length of stay on demand. These scenario impacts can then easily be compared to the baseline
- Tool further supports strategic planning through an optimiser calculation. If a user wants to achieve a target level of occupancy, e.g. 92%, they receive an indication of either the change in admissions or length of stay required to achieve this target.





Taking the temperature of connected planning in the NHS







| Level | Maturity Characteristics |
|---------------------------|--|
| Level 1: Establishing | Traditional management maturity focusing on the past. Annual budgeting process with rigid metrics. Functional/silo management with few aligned objectives and measures. Defensive functional behaviours. |
| Level 2: Emerging | Basic elements defined with KPI accountability and structure. Focus on demand/capacity tactical balancing. Basic understanding of planning process. Early recognition of integrated planning importance. Challenging behaviours but not yet team working. |
| Level 3: Capable | Integrated business plans with scenario planning. Processes used to create annual business plans. Business decisions not transactional; team working. Risk assessed, structured organisation with clear planning roles. Generally clear planning processes. |
| Level 4: Leading | Focus on planning process optimisation. Optimisation through scenario planning and robust modelling. Continuous plan reconciliation with strategic agility. Clear visualisation and synchronisation of changes. |
| Level 5: Best Practice | Structural modelling with automation. Strategic alignment with long-term focus. Fully optimised operations with organisational agility. Seamless integration across all levels. Comprehensive integration of plans and accurate assumptions. Fully clear planning processes, enabling continuous improvement and connected forecasts. |
| | Level 1: Establishing |







Open Discussion:

We invite the audience to ask questions and share their thoughts.

Thank you. We are dedicated to supporting your journey towards higher levels of integrated business planning maturity.

For further information and next steps, please contact: agem.integrated-planning@nhs.net

Strategy, Planning & Innovation Directorate Team:

Alison Tonge – Executive Director of Strategy, <u>alison.tonge1@nhs.net</u> Dr. Olu Akinremi – Value Implementation Lead, <u>olu.akinremi@nhs.net</u> Katya Anthony – Value Implementation Lead, <u>katya.anthony@nhs.net</u> David McDwyer – Advanced Analytics Lead, <u>david.mcdwyer@nhs.net</u>











NHS Arden & GEM CSU IBP Maturity Self Assessment Tool











Arden&GEM Integrated Resource Planning Network

HELPING SYSTEMS TO IMPROVE VALUE





www.ardengemcsu.nhs.uk

contact.ardengem@nhs.net





- Urgency How Immediate is the need to address the challenge ?
- Impact How significantly does the challenge impact on the health & care system ?
- Strategic Alignment Does solving the challenge align with our strategic objectives ?
- Connected Planning How will connected planning help address this challenge ?







- What challenges are highest priority to address in next 6-12 months?
- What would be your measures of success a year from now ? (savings , enhanced productivity, reduced waiting lists etc)
- Key next steps ?
- Identified leads to take forward ?







West Yorkshire Association of Acute Trusts (WYAAT)

Ben Roberts

Associate Director of Finance



₩ WYAATProgramme@nhs.net

℞ wyaat.wyhpartnership.co.uk




113 2065684

West Yorkshire Association of Acute Trusts

What is WYAAT and why does it exist?

- Collaboration of the **six acute trusts** in West Yorkshire & Harrogate
- **Self-funded** by the trusts
- Forum for acute trusts; a **single voice** into the HCP
- Providing a mechanism to share best practice and learn from each other to tackle unwarranted variation or inequalities in access, outcomes and experience
- Delivery of acute trust focused change programmes
- Leadership of wider programmes on behalf of the ICS
- Facilitates clinical, operational collaboration & mutual aid
- **Prioritising** and planning **system investments** in acute services
- **Only** what the trusts do together and the decisions they take together
- Not an organisation
- Not "doing things to" the trusts




is made up of six trusts working closely together to plan health and care services across the area.








WYAAT Collaborative Programmes







Governance



Non-governance Functional Groups:







Change is going to happen







Background

- Carter Report 2016 identified the need to consolidate Pathology services
- From 112 units to 29 hub & spoke networks
- Consolidating LTHT, CHFT & MYTT = "The Collaborative"
- Key enabler, procuring a single MSC covering:
 - 80% of testing volume of the 4th biggest ICS
 - For 7 years + 7 years
 - Including growth
 - Regional Genomics wet lab
 - Covid?
- £475m contract, in the one of the most litigious markets






Competing Priorities








The Plan







The Plan



3.5

Years



The market says....

- No one will bid without committed volumes
- No one will bid with inflation controls
- No one will bid with our KPIs
- No one will accept our T&Cs





The market says....

- No one will bid for no committed volumes
- No one will bid with inflation controls
- No one will bid with our KPIs
- No one will accept our T&Cs
- We had multiple bidders at every stage!






Legal Requirement

Fair, transparent & proportionate





The Challenge







Good News Story







The Good News cont.

- Individual procurements = £12m of savings
- As a collaborative = £30m of savings
- Enabling a further £39m from consolidation
- 1st time versus 4th time
- Sharing the learning





We've Changed the Game

"And we can infer from the fact that late last month, it decided to drop the challenge, freeing up the trusts to continue with awarding the contract to Siemens, <u>that the original</u> <u>calculations had changed</u>."

HSJ Daily Insight: 6th July 2023





Got a few dinners out of it....








Critical to Success







Questions





East Midlands HFMA Conference

NUH WAVE & GIRFT

Kim Fletcher – Transformation Programme Lead – WAVE

Kim.Fletcher@nuh.nhs.uk

Scott Hodgson – Head of Clinical Accounting & Costing Transformation

Scott.Hodgson@nuh.nhs.uk



Concentrate on....

- Improvement Methodology WAVE (Working to Achieve Value & Excellence)
- Evolution of GIRFT (Getting It Right First Time)
- How we use data to improve



Working to Achieve Value & Excellence (WAVE)

The purpose of WAVE is to facilitate Specialties in identifying and scoping for delivery projects which contribute to NUH Strategic goals covering operational, financial and patient risk.

The WAVE cycle is 17 weeks in total with weekly cadence – aim for 12 specialties p/a

Core Specialty Representation - Head of Service, Matron, SGM/AGM


Core Corporate Representation – Programme Lead, PLICS, Finance, Data Analyst


3 stage process - Data Cleanse, QI/Waste and Planning with gateway approvals by the DLT and Exec approval of the prioritised projects which have been shaped for delivery at the end of the WAVE

Exec supported process



Overview of key activities, expectations & outputs





What's Working Well...

- Nationally Recognised as Best Practice (EVO One NHS Finance, HFMA Costing Awards, ICB Value for Money, Projects national/international awards)
- Articles within HFMA Spines & Paediatric WAVES
- Financial Opportunities 6 years to 19/20 £51m identified, £29.5m achieved (56%)
- QI/Waste Opportunities 20/21 to current
 - 236 projects
 - £23m identified (129 prioritised projects)
- Huge Clinical buy-in
- Link into wider system for improvements across the ICB Mobile Stroke Unit & Palliative Care Virtual Ward plus Breast/Urology WAVE across the ICB inc Sherwood Forest Trust
- Creating sustainable continuous improvement long list of opportunities, training, skills, medium term strategic plans formulated for services
- Delivery Resources



Programmes/Projects Outcomes – last 12 months

- Development of Business cases and funding approved for
 - Paediatric Medical Day Case Unit
 - Renal Home Therapies rightsizing
 - Breast 2ww pathway
- Design and development of new MRI Express pathway
- Funding for play specialist intervention in GA MRI
- Development of new nurse led discharge protocol & training within Paeds Day Case surgery
- SDEC both Adults & Paeds
- Genomics Nanopore Technology
- Mobile Stroke Unit
- Virtual Wards
- Reducing Health Inequalities for 'Was Not Bought' in Paeds OP
- 'Trigger Tool' for Palliative Care Patients
- Combined Hand Surgery Service (T&O & Plastics)



WAVE Evaluations (last 15 services)

| • | - How would yo | | | | | | | | | | | |
|------------------------|---|------------------------------|-----------------------------|------------------------------|----------------------------|-----------------------------|---------------------------|-----------------------------|---------------------|-----------------------------|-----------------------------------|-------|
| _ | Pre Wave: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| - | Post Wave: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| 02 | – How would yo | urates | | urrentu | Inders | tanding | r of the | | svstem? | | | ••••• |
| QZ | Pre Wave: | 1 | your c | | 4 | 5 | ; or ure | 7 | o | 0 | 10 | |
| _ | | - | 2 | Ŷ | 4 | 5 | 6 | Ó | 0 | 9 | | |
| _ | Post Wave: | 1 | Z | 3 | 4 | 5 | 0 | | 8 | 9 | 10 | |
| Q3 | - How would you | ı rate y | our cu | urrent u | nderst | tanding | of Was | ste and | l Quality | Impro | /ement? | ••••• |
| - | Pre Wave: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| _ | Post Wave: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| | | | | | | | | | | | | |
| Q4 _ | - How likely are y Pre Wave: Post Wave: | you to 1 1 | useth 2 2 | e PUCS | syster 4 4 | n to ide 5 5 | entify W | /aste 8 7 7 | k Quality 8 8 | r Impro 9 9 | vement opportunities? 10 10 | |
| _ _ | Pre Wave: Post Wave: | 1 1 | 2 2 | 33 | 4 | 5 5 | 6 | 7 7 | 8 8 | 9 9 | 10 10 | |
| _ _ | Pre Wave: Post Wave: - How would you | 1 1 | 2 2 Your cu | 3 3 urrent u | 4 | 5 5 | 6 6 0 0 f the | 7 7 | 8 8 | 9 9 | 10 10 atrix)? | |
| _ _ | Pre Wave: Post Wave: - How would you Pre Wave: | 1 1 I rate y 1 | 2 2 Your cu 2 | 3 3 urrent u 3 | 4 4 nderst 4 | 5 5 anding 5 | 6 6 of the 6 | 7 7 Trust F 7 | 8 8 | 9 9 :em (N 9 | 10 10 atrix)? 10 | |
| _ _ | Pre Wave: Post Wave: - How would you | 1 1 I rate y | 2 2 Your cu | 3 3 urrent u | 4 | 5 5 | 6 6 0 0 f the | 7 7 | 8 8 | 9 9 | 10 10 atrix)? | |
| _ _ Q5 _ _ | Pre Wave: Post Wave: - How would you Pre Wave: | 1 1 I rate y 1 1 | 2 2 vour cu 2 2 | 3 3 urrent u 3 3 | 4 4 nderst 4 4 | 5 5 anding 5 5 | of the 6 6 | 7 7 Trust F 7 7 | 8 8 PMO syst | 9 9 :eem (N 9 9 | 10 10 atrix)? 10 | |
| _ _ Q5 _ _ | Pre Wave: Post Wave: - How would you Pre Wave: Post Wave: | 1 1 I rate y 1 1 | 2 2 vour cu 2 2 | 3 3 urrent u 3 3 | 4 4 nderst 4 4 | 5 5 canding 5 5 | of the 6 6 | 7 7 Trust F 7 7 | 8 8 PMO syst | 9 9 :eem (N 9 9 | 10 10 atrix)? 10 | |



Evolution of GIRFT





- NUH is an exemplar Trust for GIRFT
- HVLC from lower quartile to upper quartile nationally £2.1m efficiency
- RPRP ENT Transfer 1,400 procedures from Theatres to Outpatient Procedure Room
- GIRFT Innovation Board



Outcomes – HVLC Urology

| | 21/22 | 22/23 | M6 actual 23/24 | M6 ADJ actual 23/24 | M6 cum 23/24 | M6 ADJ cum 23/24 | Peer | Benchmark |
|-----------------------------|-------|-------|-----------------|---------------------|--------------|------------------|------|-----------|
| TURBT | 24% | 54% | 53% | 53% | 51% | 54% | 46% | 43% |
| Ureteroscopy | 39% | 62% | 57% | 61% | 55% | 61% | 76% | 80% |
| Cystoscopy | 62% | 69% | 77% | 77% | 71% | 81% | 84% | 80% |
| Minor Peno Scrotal | 93% | 92% | 100% | 100% | 97% | 98% | 89% | 96% |
| Bladder Outflow Obstruction | 13% | 10% | 47% | 47% | 42% | 46% | 28% | 25% |






You seldom improve quality by cutting costs, but you can often cut costs by improving quality.

Karl Albrecht

(quotefancy



The Data Grief Cycle




Linus's Law "given enough eyeballs, all bugs are shallow"

i.e. Let's jump into the "sandpit" and explore our Data!!




PLICS – SDEC (1)



- · Highlights where specialties are performing against SDEC targets
- Shows data by the Ambulatory Emergency Care Scenarios
- Full drill down to patient detail Sankey charts showing flow




PLICS – SDEC (2)



- Show opportunity in days against each scenario
- Full drill down to patient detail



PLICS – High Volume Low Complexity



- Highlights where specialties are performing against GIRFT targets and Peer Benchmarked Trusts
- Shows data by the GIRFT HVLC Scenarios



PLICS – HVLC Dashboard (1)

Home Clear All Selections Show detail

| GIRFT pathway | | MONTH | DC Acitivity | EL Activity | Total Activity | NUH % DC | GIRFT Suggested % | Pe |
|-----------------|-------|-------|--------------|-------------|----------------|----------|-------------------|----|
| | | | 4,429 | 4,656 | 9,085 | 48.8% | | |
| CYSTOSCOPY PLUS | 21/22 | Apr | 18 | 7 | 25 | 72.0% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | May | 25 | 22 | 47 | 53.2% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Jun | 5 | 13 | 18 | 27.8% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Jul | 17 | 13 | 30 | 56.7% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Aug | 13 | 6 | 19 | 68.4% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Sep | 12 | 17 | 29 | 41.4% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Oct | 10 | 7 | 17 | 58.8% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Nov | 34 | 11 | 45 | 75.6% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Dec | 17 | 9 | 26 | 65.4% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Jan | 22 | 4 | 26 | 84.6% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Feb | 16 | 6 | 22 | 72.7% | 80% | |
| CYSTOSCOPY PLUS | 21/22 | Mar | 12 | 10 | 22 | 54.5% | 80% | |
| CYSTOSCOPY PLUS | 22/23 | Apr | 12 | 8 | 20 | 60.0% | 80% | |
| CYSTOSCOPY PLUS | 22/23 | May | 18 | 7 | 25 | 72.0% | 80% | |
| CYSTOSCOPY PLUS | 22/23 | Jun | 18 | 8 | 26 | 69.2% | | |
| CYSTOSCOPY PLUS | 22/23 | Jul | 21 | 13 | 34 | 61.8% | 80% | |
| CYSTOSCOPY PLUS | 22/23 | Aug | 13 | 10 | 23 | 56.5% | 80% | |
| CYSTOSCOPY PLUS | 22/23 | Sep | 18 | | 31 | 58.1% | | |
| CYSTOSCOPY PLUS | 22/23 | Oct | 20 | 13 | 33 | 60.6% | 80% | |
| CYSTOSCOPY PLUS | 22/23 | Nov | 18 | | 28 | 64.3% | | |
| CYSTOSCOPY PLUS | 22/23 | Dec | 25 | | 30 | 83.3% | | |
| CYSTOSCOPY PLUS | 22/23 | Jan | 32 | | 38 | 84.2% | | |
| CYSTOSCOPY PLUS | 22/23 | Feb | 25 | | 37 | 67.6% | | |
| CYSTOSCOPY PLUS | 22/23 | Mar | 8 | | 12 | 66.7% | | |
| EndoAb | 21/22 | Apr | 1 | | 2 | | | |
| EndoAb | 21/22 | May | 3 | - | | 100.0% | | |
| EndoAb | 21/22 | Jun | | | 2 | | | |
| EndoAb | 21/22 | Jul | 1 | - | 1 | | | |
| EndoAb | 21/22 | Aug | | - | 3 | 100.0% | | |
| EndoAb | 21/22 | Oct | | | 4 | 100.0% | | |
| EndoAb | 21/22 | Nov | | | 4 | 75.0% | | |
| EndoAb | 21/22 | Dec | 2 | | 2 | 100.0% | | |
| | 21/22 | | | | 2 | | | |
| EndoAb | | Jan | | | | | | |
| EndoAb | 21/22 | Feb | 2 | | 2 | 100.0% | | |
| EndoAb | 21/22 | Mar | 2 | | 2 | | | |
| EndoAb | 22/23 | Apr | | | 2 | 100.0% | | |
| EndoAb | 22/23 | May | (| 1 1 | 1 | 0.0% | 98% | |

- Shows GIRFT pathway by month and %DC achieved against target and Peers
- Filters for Specialty, Location, POD, Year and Month
- Full drill down to patient detail



ELECTIVE ORTHOPAEDICS

BARCLAY THORACIC UNIT CARREL WARD CHILDRENS AMBULATORY (CRITICAL CARE DIRECTOR#

ENT GENERAL SURGERY GYNAECOLOGY UROLOGY

CSDC DAY SURGERY UNIT

Aug Sep Oct Nov Dec Jan Feb

SELECT YEAR 21/22 22/23 SELECT MONTH

PLICS – HVLC Dashboard (2)

me Clear All Selections Show detail

| | | YEAR | MONTH | DC Activity | EL Activity | Total Activity | NUH % DC |
|--|-------------------|---------|-----------|-------------|-------------|----------------|----------|
| | | | | 429 | 234 | 663 | 65% |
| ecified diagnostic endoscopic examination of bladder | CYSTOSCOPY PLUS | S 21/22 | Apr | | 5 2 | 7 | 71% |
| nostic endoscopic examination of bladder using rigid cystoscop | e CYSTOSCOPY PLUS | S 21/22 | Apr | 3 | 3 1 | 4 | 75% |
| ion of meatus of urethra | CYSTOSCOPY PLUS | S 21/22 | Apr | 3 | 3 1 | 4 | 75% |
| ion of urethra NEC | CYSTOSCOPY PLUS | S 21/22 | Apr | 4 | 1 O | 4 | 100% |
| nostic endoscopic examination of bladder and biopsy of lesion | o CYSTOSCOPY PLUS | S 21/22 | Apr | | 1 | 2 | 50% |
| scopic dilation of urethra | CYSTOSCOPY PLUS | S 21/22 | Apr | | 1 | 2 | 50% |
| scopic lithopaxy | CYSTOSCOPY PLUS | 5 21/22 | Apr | (| 1 | 1 | 0% |
| al urethrotomy | CYSTOSCOPY PLUS | S 21/22 | Apr | : | L O | 1 | 100% |
| ion of urethra NEC | CYSTOSCOPY PLUS | 5 21/22 | May | 8 | 3 2 | 10 | 80% |
| nostic endoscopic examination of bladder using rigid cystoscop | e CYSTOSCOPY PLUS | S 21/22 | May | 1 | 3 5 | 8 | 38% |
| ecified diagnostic endoscopic examination of bladder | CYSTOSCOPY PLUS | S 21/22 | May | 4 | 1 3 | 7 | 57% |
| ion of meatus of urethra | CYSTOSCOPY PLUS | S 21/22 | May | | 5 2 | 7 | 71% |
| scopic lithopaxy | CYSTOSCOPY PLUS | 5 21/22 | May | (| 5 | 5 | 0% |
| al urethrotomy | CYSTOSCOPY PLUS | S 21/22 | May | 4 | 1 1 | 5 | 80% |
| scopic dilation of urethra | CYSTOSCOPY PLUS | S 21/22 | May | | L 3 | 4 | 25% |
| nostic endoscopic examination of bladder and biopsy of lesion | o CYSTOSCOPY PLUS | S 21/22 | May | (| 1 | 1 | 0% |
| ecified diagnostic endoscopic examination of bladder | CYSTOSCOPY PLUS | S 21/22 | Jun | : | L 6 | 7 | 14% |
| nostic endoscopic examination of bladder and biopsy of lesion | o CYSTOSCOPY PLU | S 21/22 | Jun | (| 2 | 2 | 0% |
| copic extraction of calculus of bladder NEC | CYSTOSCOPY PLUS | S 21/22 | Jun | (| 2 | 2 | 0% |
| nostic endoscopic examination of bladder using rigid cystoscop | e CYSTOSCOPY PLUS | 5 21/22 | Jun | | 1 | 2 | 50% |
| ion of urethra NEC | CYSTOSCOPY PLUS | S 21/22 | Jun | (| 1 | 1 | 0% |
| scopic lithopaxy | CYSTOSCOPY PLUS | S 21/22 | Jun | (| 1 | 1 | 0% |
| ion of meatus of urethra | CYSTOSCOPY PLUS | S 21/22 | Jun | | L O | 1 | 100% |
| scopic dilation of urethra | CYSTOSCOPY PLUS | S 21/22 | Jun | | L O | 1 | 100% |
| al urethrotomy | CYSTOSCOPY PLUS | S 21/22 | Jun | | LO | 1 | 100% |
| ion of urethra NEC | CYSTOSCOPY PLUS | S 21/22 | Jul | 8 | 3 2 | 10 | 80% |
| nostic endoscopic examination of bladder and biopsy of lesion | o CYSTOSCOPY PLU | S 21/22 | Jul | : | L 3 | 4 | 25% |
| scopic lithopaxy | CYSTOSCOPY PLUS | S 21/22 | Jul | | L 3 | 4 | 25% |
| on of meatus of urethra | CYSTOSCOPY PLUS | S 21/22 | Jul | 3 | 3 0 | 3 | 100% |
| ostic endoscopic examination of bladder using rigid cystoscop | e CYSTOSCOPY PLUS | S 21/22 | Jul | | L 1 | 2 | 50% |
| scopic dilation of urethra | CYSTOSCOPY PLUS | S 21/22 | Jul | | L 1 | 2 | 50% |
| ecified diagnostic endoscopic examination of bladder | CYSTOSCOPY PLUS | S 21/22 | Jul | | 1 | 2 | 50% |
| scopic extraction of calculus of bladder NEC | CYSTOSCOPY PLUS | S 21/22 | lut | (| 1 | 1 | 0% |
| Scenario | D | ominant | Procedure | | | HRG | |

- Dashboard showing GIRFT pathway by procedure
- Filters for Location, Year and Month
- Full drill down to patient detail



PLICS – BADS Dashboard (1)

BADs - Opportunity

Tabular View - For Export

| Specialty | Patients | Avg LoS | LOS <24HRS (Daycase) | LOS <24HRS (Elective) | LOS <24HRS (Combined) | LOS 24- 48HRS | LOS 48- 72HRS | 0 Night Stay Target | 1 Night Stay Target | 2 Night Stay Target |
|---|----------|---------|-------------------------|--------------------------|-----------------------|------------------|------------------|------------------------|------------------------|------------------------|
| Breast Surgery | | | | | | | | | | |
| Axillary dissection / clearance | 29 | 1.14 | 41 % | 45 % | 86 % | 14.% | 0 % | 95 % | 5 % | |
| Incision of breast | 3 | 1.67 | | 67 % | 67 % | 0 % | 33 % | 100 % | 0 % | () () |
| Insertion, revision, removal, renewel of breast prothesis | 21 | 1.05 | 86 % | 10 % | 95 % | 5 % | 0 % | 99 % | 1 % | 10 |
| Mammoplasty (reduction, augmentation, revision) | 13 | 1.15 | 54 % | 38 % | 92 % | 0 % | 8 % | 75 % | 25 % | 8 |
| Mastectomy without axillary surgery | 88 | 1.20 | 41 % | 47 % | 88 % | 5 % | 8 % | 75 % | 25 % | |
| Mastopexy | 4 | 1.00 | 50 % | 50 % | 100 % | 0 % | 0 % | 75 % | 25 % | 1 |
| Microdochotomy + other operations on duct of breast | 4 | 1.00 | 100 % | | 100.% | 0 % | 0 % | 100 % | 0 % | 2 (1 |
| Operations on nipple | 24 | 1.00 | 88 % | 13 96 | 100 % | 0 % | 0.96 | 100 % | 0 96 | 2 23 |
| Re-excision of margins | 18 | 1.00 | 83 % | 17 % | 100 % | 0 % | 0 % | 100 % | 0 % | |
| Sentinel lymph node biopsy | 1 | 1.00 | | 100 % | 100 % | 0 % | 0 % | 100 % | 0 % | |
| Wide local excision of breast including wire guided | 219 | 1.02 | 68 % | 31 % | 99 % | 1 % | 0 % | 99 % | 1 % | |
| mergency Surgery | | | | | | | | | | |
| Appendicectomy, including laparoscopic | 111 | 2.09 | | 19 % | 19 % | 53 % | 28 % | 15 % | 80 % | 1 |
| Evacuation of retained products of conception | 2 | 1.00 | 100 % | | 100 % | 0 % | 0 % | 95 % | 5 % | |
| Incision and drainage of perianal abscess | 77 | 1.16 | 27.% | 61 % | 88 % | 8 % | 4 % | 95 % | 5 % | |
| Incision and drainage of skin abscess | 306 | 1.24 | 20 % | 63 % | 83 % | 10 % | 7 % | 100 % | 0 % | |
| Laparoscopic cholecystectomy | 174 | 1.11 | 52 % | 40 % | 92 % | 5 % | 3 % | 25 % | 25 % | |
| MUA fracture and application of plaster cast | 249 | 1.04 | 8 % | 89 % | 97 % | 2 % | 1 % | 100 % | 0 % | <u>i</u> 16 |
| Primary reduction and open fixation of ankle | 6 | 1.17 | | 83 % | 83 % | 17 % | 0.96 | 25 % | 50 % | 2 |
| Reduction of fractured mandible | 52 | 1.96 | | 35 % | 35 % | 35 % | 31 % | 20 % | 70 % | 1 |
| Removal of foreign body from skin | 46 | 1.09 | 57 % | 35 % | 91 % | 9.96 | 0.% | 100 % | 0 % | |
| Removal of products of conception from fallopian tube (ectopic pregnancy), including laparoscopically | 1 | 2.00 | | | | 100 % | 0.% | 55 % | 40 % | |
| Repair of hand or wrist tendon | 110 | 1.11 | 72 % | 20 % | 92 % | 5 % | 3 % | 95 % | 5 % | |
| Suture of skin wound | 138 | 1.21 | 37 % | 49 % | 86 % | 8 % | 7 % | 75 % | 25 % | 10 |
| < | 1 | | | | | | | | | > |

- Dashboard showing Specialty and procedure highlighting areas for improvement
- Full drill down to patient detail



PLICS – BADS Dashboard (2)

BADs - Opportunity


Opportunity for savings if procedures are moved away from Inpatient setting to Day Case Setting

| Specialty | Patients | Avg LoS | PatExpense | Unit Cost | Bed Cost Saving | Opportunity By Specialty |
|--|------------|---------|-----------------------------|-----------------------------|--------------------|--------------------------|
| Emergency Surgery | 703 | 1.39 | 2,071,911.37 | £583,553.98 | £73,597 | |
| Incision and drainage of skin abscess | 306 | 1.24 | 606,858.31 | £101,143.05 | £33,033 | Emergency Surgery |
| Appendicectomy, including laparoscopic | 111 | 2.09 | 500,349.10 | £380,671.01 | £29,240 | in gan, cogar, |
| Incision and drainage of perianal abscess | 77 | 1.16 | 204,915.38 | £23,951.15 | £6,048 | |
| Repair of hand or wrist tendon | 110 | 1.11 | 358,044.38 | £29,294.54 | £2,657 | General Surgery |
| Reduction of fractured mandible | 52 | 1.96 | 280,372.99 | £155,283.50 | £1,359 | |
| Removal of foreign body from skin | 46 | 1.09 | 116,507.32 | £10,131.07 | £1,180 | Urology |
| Removal of products of conception from fallopian tube (ectopic pregnancy), including laparoscopically | 1 | 2.00 | 4,863.89 | £4,620.69 | £80 | Gynaecology |
| General Surgery | 489 | 1.22 | 1,461,838.45 | £230,187.24 | £13,636 | |
| Closure iliostomy | 5 | 2.40 | 27,204.17 | £8,161.25 | £7,246 | |
| Primary repair of inguinal hernia | 171 | 1.08 | 506,843.32 | £29,639.96 | £2,415 | Orthopaedic |
| Excision biopsy of lymph node for diagnosis (cervical, inguinal, axillary) | 58 | 1.12 | 165,701.13 | £17,141.50 | £1,142 | Breast Surgery |
| Diagnostic laparoscopy | 43 | 1.05 | 100,168.28 | £4,658.99 | £754 | |
| Repair of umbilical hernia, adult | 99 | 1.14 | 285,003.65 | £28,788.25 | £611 | Vascular |
| Laparoscopic repair of hiatus hernia with anti-reflux procedure | 3 | 1.33 | 15,816.14 | £3,690.43 | £417 | |
| Repair of recurrent inquinal hernia | 22 | 1.14 | 64,700.63 | £8,822.81 | £305 | Head and Neck |
| Treatment of anal fistula including seaton suture | 30 | 1.13 | 66,152.22 | £6,615.22 | £238 | |
| Repair of rectal mucosal prolapse | 6 | 1.33 | 17,089.81 | £2,848.30 | £221 | ENT |
| Appendicectomy, including laparoscopic | 41 | 2.20 | 169,202.03 | £135,980.65 | £198 | |
| Primary repair of femoral hernia | 11 | 1.36 | 43,957.06 | £7,992.19 | £89 | Paediatric |
| Urology | 452 | 1.23 | 1,556,870.67 | £275,552.33 | £13,218 | |
| Endoscopic resection/destruction of lesion of bladder | 218 | 1.13 | 652,196.32 | £36,199.89 | £6,988 | Opthalmology |
| Endoscopic insertion of prosthesis into ureter | 106 | 1.30 | 354,662.28 | £86,992.63 | £2,238 | opmannology |
| Endoscopic laser fragmentation of calculus of kidney | 23 | 1.35 | 137,782.36 | £35,943.23 | £1,193 | |
| Ureteroscopic extraction of calculus of ureter Total | 57 5372 | 1.26 | 220.395.47 17,740,490.32 | £38.665.87 £3.180.210.76 | £1.130 £141,550 | ✓ £0.0M £0.1M |

- Dashboard showing potential bed cost savings by specialty and procedure
- Full drill down to patient detail



Audiology - Is the current patient journey optimised?



Audiology - Is the current patient journey optimised?

<u>Discovery</u>

- Multiple patient pathways
- Lost patients
- Interaction with ENT not efficient

Solutions

- Audiologists Transformation into Primary Care Model ICB
- Optimisation of Best Practice Pathways
 - Within NUH
 - New Nationally Commissioned Services
- Improved Systems & Processes
 - Online ordering of spare parts & Online hearing tests
 - Patient initiated Follow-ups
 - Skill mix improvements



HCOP – Right Patient, Right Pathway (Bed)

Comparison between HCOP and Cardiology on the top four cardiac type conditions that present in HCOP:

| FrailtyScore 0. Not Populated 1. Very fit | م 256 6 | Spells with a Frailty Score or cared for by HCOP | | | | | | | | | | | | | | |
|---|---------------|--|-----|-------------------------------|-----|----------------------|-------------|---------------|----|-------------|---------------------|--------------|---------|-----------------------------------|--|--|
| 2. Well 3. Managing well 4. Vulnerable | 160 | HRG Root | • • | Discharging Ward Specialty | • • | Activity (Spells) | Average LOS | within 7 Davs | | Red Days (% | Average Red Days | Average Cost | of LOS) | Average Medically Safe Days | | |
| 5. Mildly frail | 237 | Heart Failure or Shock | | Healthcare of Older People | ± | | | | | | | | | | | |
| 6. Moderately frail | 511 | field Failure of Shock | | Cardiology | ± | 10 | | | | | | -£4,961 | | | | |
| 7. Severely frail | 245 | Syncope or Collapse | | Healthcare of Older People | ± | | | | | | | L -£3,214 | | | | |
| 8. Very severely frail | 10 | | | Cardiology | ± | | | | | | | | | | | |
| 9. Terminally ill | 3 | Arrhythmia or Conduction | | Healthcare of Older People | ± | | | | | | | L -£3,315 | | | | |
| Discharge Year | ٩ | Disorders | | Cardiology | ± | | | | | | | | | | | |
| Discharge real | 0010 | Unspecified Chest Pain | | Healthcare of Older People | + | | | 9% | | | | L -£2,201 | | | | |
| | 2019 | | | Cardiology | ± | 2 | 0 2 | 10% | 5% | 0% | (| 0 -£1,130 | 0% | • | | |
| | 2020 2021 2 | | | | | | | | | | | | | | | |
| | - 1202 | | | | | | | | | | | | | | | |
| Age Groups | م ا | | | | | | | | | | | | | | | |
| 56-60 | 1 🔺 | | | | | | | | | | | | | | | |
| 61-65 | 3 | | | | | | | | | | | | | | | |
| 66-70 71-75 | 29 95 | | | | | | | | | | | | | | | |
| 76-80 | 287 | | | | | | | | | | | | | | | |
| 81-85 | 391 | | | | | | | | | | | | | | | |
| 86-90 | 455 | | | | | | | | | | | | | | | |
| 91-95 | 315 | | | | | | | | | | | | | | | |
| 96-100 | 67 | | | | | | | | | | | | | | | |
| 100+ 0-5 | 5 | | | | | | | | | | | | | | | |
| 0-5 | 0 🗸 | | | | | | | | | | | | | | | |

Initial findings show elderly patients currently in HCOP beds with a frailty score 1-5 with the same primary condition but in a Cardiology bed have a lower length of stay, lower readmission rates & lower mortality.

A solution being explored, to optimise patient care is to create a Cardio-Geriatrician service or a HCOP in-reach program to support treatment of higher frailty patients with cardiac conditions.

HCOP – Right Patient, Right Pathway (Bed)

- Patient journey
- Frailty Scores
- Is the patient in the right place
- Hypothesis inpatients admitted to HCOP
 - a) Outside of their definition for the service (being over 74 and having a frailty score of at least '6. Moderately frail')
 - b) Presenting with a primary condition which would be better treated with the associated specialty. For example, Heart Failure patients to be better managed in Cardiology. Primary condition, not age.
- Exploring the data to support the three ideas to optimise inpatients in HCOP
 1) Getting patients to the right place, first time
 - 2) Variation in outcomes, by discharging specialty, primary condition, age and frailty score




3) Variation in HCOP wards

Spines – Where do I start?



Spines – Understanding my finances







NHS Supply Chain

Hamish Makanji: Head of Hospital Care Chris Morris: National Lead for Out of Hospital Care Service Development Leanne Wareing: Care Pathway Specialist (Specialised Commissioning)

Agenda



- Introductions
- Overview of NHS Supply Chain
- Functional overviews
 - Hospital Care
 - Out of Hospital Care
 - Care Pathway Team
- Opportunities to Work Better Together
- Questions

NHS Supply Chain Strategy



Our long-term Strategy guides our multi-year delivery programme to ensure we are delivering our vision of making it easier for the NHS to put patients first:



One NHS Supply Chain

We are one organisation in the eyes of our teams and stakeholders, operating efficiently as a single organisation within the NHS family.

Strengthen Resilience

We ensure availability of critical products, supporting the NHS to deliver excellent patient care.

£1 Billion of Value

We will create £1 billion of recurrent value to return to the NHS from 2030.

Our Role

We are part of the NHS and deliver a **resilient** supply chain of **clinically assured** goods and services to **health and care providers**.

| What we do | Where we support | | |
|--|--|--|--|
| Consolidate Purchasing, Deliveries and Invoices | Aggregate NHS spend for a range of medical devices and clinical consumables. Provide consolidated deliveries, picked to requisition point, to agreed delivery times. | Inventory Management Support the roll out of inventory management; generating efficiencies and supporting patient safety | |
| Clinical and Quality Assured | Provide clinical and quality assurance across all our frameworks. | | |
| Targeted Resilience | Provide resilience for a core list of products (stockholding, alternatives, supply chain mapping). | Demand Management Implement demand management control requirements on behalf of NHS England | |
| Safety | Work with regulators and suppliers to ensure product safety issues are dealt with swiftly. | | |
| Sustainability and Social Value | Deliver sustainability solutions and social value across our global supply chain. | Insights and Account Management Provide data and intelligence on savings opportunities for the NHS | |
| Innovation | Collaborate with suppliers and trusts to introduce MedTech and novel innovations that deliver value-based benefits. | | |

A New Commercial Model to Support the NHS



We operate across a wide product range: our products are grouped into **four medical** and **two non-medical categories**, covering **134 awarded product and service categories**.

| NHS Supply Chain | | | | | | | |
|--|---------------------------------|-----------------------|-------------|-------------|------------------------------------|--|--|
| Medical | | | Capital | Non-Medical | | | |
| Medical and Surgical Consumables | Rehabilitation and Community | Medical Technology | Diagnostics | Food | Facilities and Office Solutions | | |
| | Internal | Outsourced partners | | | | | |
| Internal delivery | | | Foodbuy | NOECPC | | | |
| Commercial Centre of Excellence | | | | | | | |
| Supplier Relationship Management | | | | | | | |
| Sourcing Execution | | | | | | | |

Being Easier to Work With



We are investing in an ambitious transformation programme and evolving how we work to ensure customer needs are at the core of our decision making.

Technology modernisation

Aligning to ICS working

Focus on NHS needs through engagement

Working as One NHS Supply Chain

Focus on end-to-end patient pathways



Hospital Care Strategy



Partner expertly with our customer - holding influence and key relationships internally to source expert support

| Deliver value to the NHS | Focus on end-to-end value, including, but not limited to cash releasing savings Identify opportunities for increased value based on projected demand and benefit for the whole ICS system, rather than on historic usage, tailoring the opportunities based on the needs of the ICS and its population and priorities |
|----------------------------------|--|
| Align our structure to ICS | Scale our activity and focus to ICS level Develop our reporting capabilities to provide greater insight and potential opportunities |
| Develop ICS wide relationships | Developing relationships beyond finance and procurement to support ICS priorities moving to a mutually beneficial partnership model |
| Develop capability of our people | Embed the 'Customer Academy' building capability across the team to support the evolving needs of our NHS partners and care providers |
| Articulate our value offer | Develop a baseline of service delivery to our customers with clear demonstrable value |

Out of Hospital Care: How We Are Organised To Deliver



Natalie Royston Head of Out of Hospital Care



Stuart Milhench Home Delivery Service (HDS) Manager



Will Gilbert Out of Hospital Care Service Manager



Data Manager

Deane Bridges Out of Hospital Care



Supply Chain

Chris Morris National Lead for Out of Hospital Care Service Development

Existing Out of Hospital Care Services



Supply Chain

Direct-to-Healthcare Professional:


• NHS Supply Chain can expand our service where there is an existing delivery footprint, for example increasing the range of products delivered to GP Surgeries, District Nurse bases and Clinics.

Direct-to-Patient:

- Opportunity to optimise continence product ranges system-wide generating cost savings
- Further savings and sustainability potential in washable products

Developing New Services





The Out of Hospital Care team has a dedicated Service Development function to explore new services with NHS customers and better understand priority categories and services to help the NHS save lives and improve health.

Care Pathway Team



Partner Expertly with Integrated Care Systems to:

• Support delivery of the NHS Quadruple Aim:



- Support delivery of objectives set out in the 2024 / 2025 priorities and operational planning guidance:
 - Deliver a balanced net system financial position
 - Eliminate 65-week waiters
 - Deliver 107% elective activity target
 - 95% of patients to receive a diagnostics test within 6 weeks

Care Pathway Team 2024 / 2025 Priorities



To Partner Expertly with Integrated Care Systems to:

Drive the adoption of clinical practice featured in our Value Based Procurement (VBP) Case Studies within identified care pathways

Drive the adoption of Innovative Products, Devices and Services, including those featuring on the MedTech Funding Mandate Policy within identified care pathways


Develop Integrated Care System-led activities that address care pathway clinical pain points and / or operational challenges creating future VBP Case Studies

Efficiency and Productivity Methodology



- Hospital Episode Data from 23/24
- Dependency: quality of NHS provider organisation clinical coding
- Applies efficiency / financial values signed off in VBP case studies
- Applies principles from NHS procurement value and savings methodology (NHSE)
- Assumes GIRFT best practice, NICE recommendations and MedTech Funding Mandate (MTFM) policy adoption

Recent Developments



Productivity and Efficiency Savings - Example



| System Financial Modelling- Example | | | | | | |
|-------------------------------------|---|---|---|---|--|--|
| VBP Opportunity Name | Assumed Productivity and Efficiency (P&E) Saving Per Procedure / Patient / NHS Provider | Estimated Annual P&E Savings Based On Financial Modelling and Assumptions | Assumed Number of Procedures / Patients / NHS Providers | Comments | | |
| Transnasal Endoscopy | £30.57 per procedure | £0.3m | | Using HES (code G45) for 23/24. Weighted at 85% as per case study. Excludes reported values from Case Study Site Royal United Hospitals Bath NHS Foundation Trust | | |
| BARD tray / CAUTI Reduction | £1,968 per procedure | £0.2m | 785 | Using updated HES Data (Code M47) for 23/24. Weighted at 50% reduction Excludes reported values from Case Study Site Case Study Site - University Hospitals of North Midlands NHS Trust | | |
| Disposable Elastomeric Pump (IV) | £500,000 per acute provider | £2m | 4 | Based on number of NHS Providers per ICS Excludes reported values from Case Study Site Case Study Site - Oxford University Hospitals NHS Foundation Trust | | |
| Artiss skin sealant | £38,571 per acute provider for LoS <2.4 days or £805 per patient for LoS >2.5 days | £0.1m | 70 | Based on the number of relevant acute providers in ICB undertaking the procedures (codes F44) Excludes reported values from Case Study Site Case Study Site - Manchester University NHS Foundation Trust | | |
| APOS | £4,700 per patient | £0.9m | 186 | Applies £4,700 per patient saving over a 3-year period based upon NICE MTG-76 Resource Impact Assessment No case study published as yet. | | |
| Remote Monitoring | £424 per patient | £0.5m | 1,085 | Using HES (codes K60 & K61) for 23/24. Excludes reported values from Case Study site Case Study Site - University Hospitals of Leicester NHS Trust. Excludes modelling for Barts Health NHS Trust and Dorset County Hospital NHS Foundation Trust. | | |
| Pacenet | £150,000 per acute provider | £0.6m | 4 | Based on number of in-scope NHS Acute Provider Providers (not all NHS Providers will have a need for Pacenet) Case Study to be published - to exclude modelling for Royal Free London NHS Foundation Trust and London North West University Healthcare NHS Trust | | |
| Total opportunity | | £4.6m | | | | |

Opportunities to Work Better Together



Work in partnership with NHS Supply Chain to unlock value:-

- Encourage your teams to continue to share data, implement workplans, and understand new opportunities
- Engage with us to deliver value opportunities in all care settings for wound care and continence
- Partner with us to develop new services that drive operational efficiency, improve the patient experience and deliver system savings
- Champion the implementation of VBP opportunities to support the delivery of the 2024 / 2025 priorities and operational planning guidance objectives





Thank you

№ @NHSSupplyChain
 in NHS Supply Chain
 ⊕ www.supplychain.nhs.uk

Supply Chain Coordination Limited (SCCL) is the Management Function of the NHS Supply Chain

Comfort Break: 10 Minutes





NHS Trusts and Provider Collaborative Engagement Session

Provider Selection Regime (PSR)

Collette Palmer - Associate Director of Procurement (Specialised Commissioning)



Provider Selection Regime (PSR) – Background and Overview

Arden and Greater East Midlands Commissioning Support Unit

PSR - regulations came into force on **01**st **January 2024** and replaced:

The National Health Service (Procurement, Patient Choice and Competition) (No 2) Regulations 2013 (PPCCR 2013) and,

The Public Contracts Regulations 2015 (PCR 2015).

PSR has been designed to **support greater integration**, **wider collaboration** across systems, offer **flexible and proportionate processes** for selecting providers of **health care services**.

Organisations referred to as 'Relevant Authorities' are required to follow PSR:

Integrated Care Boards (ICBs),

- NHS England (NHSE),
- NHS Trusts and Foundation Trusts,
- Local Authorities,
- Combined authorities.

Very important to note that these new regulations only apply to **Clinical Healthcare Services** Procurement unless it is construed as a mixed procurement.



Key points - updates

Ith and social care systems support


- New Contracts can only be awarded using the Most Suitable Provider or Competitive Process. Commissioners cannot directly award new contracts except for reasons of urgency (maximum 12 months).
- **Direct Award Process A** existing service / existing provider is only capable provider i.e. Emergency Services (Blue Light etc.)
- Direct Award Process B i.e. elective services led by a consultant or mental health care professional where patients have a legal right to Choice. Cannot limit number of providers. Have to allow providers to express an interest and be advised of outcome within 6 weeks.
- **Direct Award Process C** is proving to be resource intensive for Commissioners. All DAPC processes need to utilise all 5 Key Criteria within Annex D of the Statutory Guidance (examples of sufficient evidence are also provided).
- Demands greater transparency. Commissioners **MUST** place a notice when **ANY** contract is awarded. Dependent on the process followed this can vary from 2 notices to 4 notices.
- As part of the transparency requirements there are a number of requirements placed on Relevant Authorities in terms of **record keeping**. These are considerably more onerous than previous requirements.
- The Independent Patient Choice & Procurement Panel referral form is now live, and providers can now access and complete to submit their representations.

Key points - updates

- Arden and Greater East Midlands Commissioning Support Unit
- For the majority of processes, including DAP C, Commissioners must apply five "key criteria" and be able to demonstrate how they have done this. The key criteria are:
 - Quality and innovation
 - Value
 - Integration, collaboration and service sustainability
 - Improving access, reducing health inequalities and facilitating choice
 - Social Value
- Thresholds for **contract modification** have been amended so that the modification is considered material if:
 - The changes render the contract **materially different** in character; or
 - The changes are **OVER £500K AND represent OVER 25%** of the original contract value (where the modification is attributable to a decision of the Relevant Authority as opposed to being made in response to external factors beyond the control of the Relevant Authority).
- A system whereby relevant authorities must consider "**representations**" bought by providers must be in place. These:
 - Must adhere to certain timescales (in terms of a "standstill period")
 - Can be escalated to an **advisory NHSE panel** who will scrutinise process but will only **"advise"** relevant authorities on the correct course of action
 - If still disgruntled, ultimate remedy is Judicial Review.

PSR – what we provide our customers/partners

- Experts in the delivery of PSR already undertaking numerous processes under the regime on a daily basis
- Advice and guidance on best approach
- Support in governance and record-keeping
- Represented on the 'Representation review panel'
- Training and development
- As results of panel investigations (from across the country) are published we will share and commence lessons learned sessions to ensure continued learning





- Urgency How Immediate is the need to address the challenge ?
- Impact How significantly does the challenge impact on the health & care system ?
- Strategic Alignment Does solving the challenge align with our strategic objectives ?
- Connected Planning How will connected planning help address this challenge ?







- What challenges are highest priority to address in next 6-12 months?
- What would be your measures of success a year from now ? (savings , enhanced productivity, reduced waiting lists etc)
- Key next steps ?
- Identified leads to take forward ?





Close: Chairs Summary



